tiprankstipranks
MaaT Pharma (FR:MAAT)
:MAAT
France Market
Want to see FR:MAAT full AI Analyst Report?

MaaT Pharma (MAAT) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

MAAT Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
MaaT
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MAAT Stock 12 Month Forecast

There Are No Analyst Ratings for FR:MAAT In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

MAAT Financial Forecast

MAAT Earnings Forecast

The previous quarter’s earnings for MAAT were -€0.95.
The previous quarter’s earnings for MAAT were -€0.95.

MAAT Sales Forecast

The previous quarter’s earnings for MAAT were €2.10M.
The previous quarter’s earnings for MAAT were €2.10M.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on FR:MAAT
Stifel Nicolaus
Stifel Nicolaus
€19
Buy
244.83%
Upside
Reiterated
03/31/26
MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential
Kepler Capital  Analyst forecast on FR:MAAT
Kepler Capital
Kepler Capital
€17
Buy
208.53%
Upside
Reiterated
03/31/26
Kepler Capital Sticks to Its Buy Rating for MaaT Pharma (MAAT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on FR:MAAT
Stifel Nicolaus
Stifel Nicolaus
€19
Buy
244.83%
Upside
Reiterated
03/31/26
MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential
Kepler Capital  Analyst forecast on FR:MAAT
Kepler Capital
Kepler Capital
€17
Buy
208.53%
Upside
Reiterated
03/31/26
Kepler Capital Sticks to Its Buy Rating for MaaT Pharma (MAAT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MaaT Pharma

3 Months
Christophe dombuKepler Capital
Success Rate
8/17 ratings generated profit
47%
Average Return
-4.32%
Copying Christophe dombu's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -4.32% per trade.
1 Year
Clémence ThiersStifel Nicolaus
Success Rate
4/15 ratings generated profit
27%
Average Return
-20.57%
Copying Clémence Thiers's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -20.57% per trade.
2 Years
Clémence ThiersStifel Nicolaus
Success Rate
0/15 ratings generated profit
0%
Average Return
-51.47%
Copying Clémence Thiers's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -51.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MAAT Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
2
2
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
2
2
0
0
In the current month, MAAT has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MAAT average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

MAAT Stock Forecast FAQ

What is FR:MAAT’s average 12-month price target, according to analysts?
Currently, no data Available
What is FR:MAAT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for FR:MAAT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is MaaT Pharma a Buy, Sell or Hold?
      Currently, no data Available
      What is MaaT Pharma’s share price target?
      Currently, no data Available
      What do analysts say about MaaT Pharma?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of MaaT Pharma?
      To buy shares of FR:MAAT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.